CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting
06 Novembre 2023 - 2:30PM
Business Wire
Public Meeting Scheduled for November 29,
2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a wearable medical robotics company that offers
increased functionality for those suffering from neurological
disorders and upper-limb paralysis, today announced that the
Centers for Medicare & Medicaid Services (CMS) posted a
proposed Medicare Durable Medical Equipment, Prosthetics,
Orthotics, and Supplies (DMEPOS) fee schedule payment rate for the
MyoPro® to be discussed at CMS’ bi-annual Healthcare Common
Procedure Coding System (HCPCS) Public Meeting, scheduled for
November 29, 2023.
CMS has proposed fee schedule rates for the two HCPCS codes
describing the MyoPro, L8701, which is our Motion W device, and
L8702, which is our Motion G device, of $31,745.42 and $62,457.28,
respectively. On November 1, 2023, CMS published its final rule
that classifies the MyoPro as a brace and will enable reimbursement
on a lump sum basis once the rule becomes effective on January 1,
2024.
“We’re pleased to see the process moving forward to determine a
national fee schedule rate from CMS for the MyoPro,” stated Paul R.
Gudonis, Myomo’s Chairman and CEO. “This is an important milestone
for the Company and an important step in facilitating access to the
MyoPro for qualified Medicare Part B beneficiaries with long-term
muscular weakness or partial paralysis.”
The preliminary payment determinations published by CMS for
discussion at the public meeting are only proposed fee schedule
rates. The Company cannot provide any assurance that these rates
will be finalized and published in their current amounts, or at
all.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
improved arm and hand function for those suffering from
neurological disorders and upper-limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper-limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of certain patients suffering from CVA
stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is
currently the only marketed device that, sensing a patient’s own
EMG signals through non-invasive sensors on the arm, can restore an
individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and
reduce their cost of care. Myomo is headquartered in Boston,
Massachusetts, with sales and clinical professionals across the
U.S. and representatives internationally. For more information,
please visit www.myomo.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company’s future business expectations, including expectations
for the fees published by CMS for the MyoPro which are subject to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors.
These factors include, among other things:
- We have a history of operating losses and our financial
statements for the period ended June 30, 2023 include disclosures
regarding there being substantial doubt about our ability to
continue as a going concern;
- our ability to obtain sufficient reimbursement from third-party
payers for our products, including CMS for Medicare Part B
patients;
- our revenue concentration with a particular insurance payer as
a result of focusing our efforts on patients with insurers who have
previously reimbursed for the MyoPro;
- our ability to continue normal operations and patient
interactions without supply chain disruption in order to deliver
and fit our custom-fabricated device;
- our marketing and commercialization efforts;
- our dependence upon external sources for the financing of our
operations, to the extent that we do not achieve or maintain cash
flow breakeven;
- our ability to effectively execute our business plan and scale
up our operations;
- our expectations as to our product development programs,
and;
- general market, economic, environmental and social factors that
may affect the evaluation, fitting, delivery and sale of our
products to patients.
More information about these and other factors that potentially
could affect our financial results is included in Myomo’s filings
with the Securities and Exchange Commission, including those
contained in the risk factors section of the Company’s annual
report on Form 10-K, quarterly reports on Form 10-Q and other
filings with the Commission. The Company cautions readers not to
place undue reliance on any such forward-looking statements, which
speak only as of the date made. Although the forward-looking
statements in this release of financial information are based on
our beliefs, assumptions and expectations, taking into account all
information currently available to us, we cannot guarantee future
transactions, results, performance, achievements or outcomes. No
assurance can be made to any investor by anyone that the
expectations reflected in our forward-looking statements will be
attained, or that deviations from them will not be material or
adverse. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or
circumstances after the date of such statements or to reflect the
occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106867030/en/
For Myomo: ir@myomo.com
Investor Relations: Kim Sutton Golodetz LHA Investor Relations
kgolodetz@lhai.com 212-838-3777
Myomo (AMEX:MYO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Myomo (AMEX:MYO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024